Why the study?
Does enoximone improve mortality and quality of life in patients with severe end stage heart failure?
Population
151 patients with severe, symptomatic end stage heart failure despite treatment with diuretics and where…
Comparison
Enoximone added to conventional treatment vs Placebo added to conventional treatment
Design
RCT, randomised, double blind
Follow-up
Planned minimum 1 year (ended early)
Authors
Loading...
Mortality harm precludes enoximone in severe HF despite QoL gains; challenges inotrope use and reinforces survival as primary trial endpoint.
Does enoximone improve mortality and quality of life in patients with severe end stage heart failure?
In patients with severe heart failure, enoximone improved quality of life but significantly increased mortality, highlighting the trade-off between symptom relief and survival with inotropic therapy.
Cowley et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: